| 证券代码：300401 | 证券简称：花园生物 | 公告编号：2026-010 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 关于可转换公司债券 2026 年付息的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、"花园转债"（债券代码：123178）将于2026年3月6日按面值支付第三年利息， 每10张"花园转债"（面值1,000.00元）利息为10.00元（含税）。 2、债权登记日：2026年3月5日（星期四） 3、付息日：2026年3月6日（星期五） 4、除息日：2026年3月6日（星期五） 5、本次付息期间及票面利率：计息期间为2025年3月6日至2026年3月5日，票面利 率为1.0%。 4、可转换公司债券上市量：120,000.00万元（1,200万张） 5、可转换公司债券上市地点：深圳证券交易所 6、可转换公司债券上市时间：2023年3月23日 6、本次付息的债权登记日为2026年3月5日。凡在2026年3月5日（含）前买入并持 有本期 ...

分红方面，花园生物A股上市后累计派现4.46亿元。近三年，累计派现1.78亿元。 机构持仓方面，截止2025年9月30日，花园生物十大流通股东中，南方中证1000ETF（512100）位居第 四大流通股东，持股347.85万股，相比上期减少4.84万股。香港中央结算有限公司位居第十大流通股 东，持股223.26万股，相比上期减少40.36万股。 2月25日，花园生物涨1.07%，成交额3.08亿元。两融数据显示，当日花园生物获融资买入额3778.56万 元，融资偿还5776.19万元，融资净买入-1997.63万元。截至2月25日，花园生物融资融券余额合计7.89 亿元。 融资方面，花园生物当日融资买入3778.56万元。当前融资余额7.87亿元，占流通市值的8.47%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，花园生物2月25日融券偿还500.00股，融券卖出800.00股，按当日收盘价计算，卖出金额1.37 万元；融券余量13.54万股，融券余额231.26万元，超过近一年90%分位水平，处于高位。 资料显示，浙江花园生物医药股份有限公司位于浙江省金华市东阳市南马镇花园村，成立日期2000 ...

（文章来源：证券日报） 证券日报网讯 2月13日，花园生物在互动平台回答投资者提问时表示，截至2026年2月10日，公司股东 总户数为24273户。 ...

Group 1 - The stock price of Huayuan Bio (300401) experienced significant fluctuations in the past week, with a peak increase of 5.98% on February 6, closing at 19.15 yuan, and a total market value of 95.65 billion yuan as of February 12 [1] - The stock showed a trading range of 12.45% and a high turnover rate, indicating active trading, with a net outflow of 39.57 million yuan from institutional investors and a net inflow of 39.57 million yuan from retail investors on February 12 [1] Group 2 - Huayuan Bio is recognized as a leader in the vitamin segment and has gained market attention as a hot stock in the chemical sector, with significant holdings by Southern Fund's CSI 1000 ETF, which owns 347.85 thousand shares (0.65% of circulating shares) but reduced its holdings by 48.4 thousand shares in the third quarter [2] - The chemical sector, particularly phosphates and vitamins, has been driven by policy and demand, with Huayuan Bio being highlighted for its vitamin D3 supply chain [2] Group 3 - Institutional ratings for Huayuan Bio are generally neutral, with a target price of 22.00 yuan, indicating a potential upside of 21.48% from the latest price [3] - The forecast for net profit growth is modest, with a projected increase of 0.18% for 2025 and a more substantial growth of 40.35% expected in 2026, while the current price-to-earnings ratio (TTM) stands at 31.69 [3] - The proportion of institutional holdings is relatively low at 0.11%, and the frequency of institutional research is average [3]

Group 1 - Garden Biologics' stock increased by 5.06%, reaching 18.68 CNY per share, with a trading volume of 356 million CNY and a turnover rate of 3.65%, resulting in a total market capitalization of 10.152 billion CNY [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Garden Biologics, having reduced its holdings by 48,400 shares to 3.4785 million shares, representing 0.65% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY. Year-to-date returns are 8.61%, ranking 1564 out of 5569 in its category, while the one-year return is 34.61%, ranking 1862 out of 4295 [2] Group 3 - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 98 days. The total asset scale under management is 137.02 billion CNY, with the best fund return during the tenure being 251.88% and the worst being -15.93% [3]

Group 1 - The company has no plans to acquire Furuixi Pharmaceutical as stated on the interactive platform [1]

Group 1 - Garden Biologics experienced a decline of 5.22% on February 9, with a stock price of 18.15 yuan per share and a trading volume of 585 million yuan, resulting in a turnover rate of 5.88% and a total market capitalization of 9.864 billion yuan [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Among the top circulating shareholders of Garden Biologics, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 48,400 shares in the third quarter, now holding 3.4785 million shares, which accounts for 0.65% of the circulating shares [2] - The estimated floating loss for the Southern CSI 1000 ETF (512100) today is approximately 3.4785 million yuan. The fund was established on September 29, 2016, with a latest scale of 78.996 billion yuan, and has achieved a 6% return this year, ranking 1533 out of 5580 in its category [2] - The fund manager, Cui Lei, has a tenure of 7 years and 96 days, with a total fund asset size of 137.02 billion yuan. The best fund return during the tenure is 279.97%, while the worst return is -15.93% [2]

证券代码：300401 证券简称：花园生物 公告编号：2026-009 债券代码：123178 债券简称：花园转债 浙江花园生物医药股份有限公司 关于花园转债预计触发赎回条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 自2026年1月21日至2026年2月6日，浙江花园生物医药股份有限公司（以下 简称"公司"）股票已有10个交易日的收盘价不低于当期转股价格13.45元/股的 130%（即17.49元/股），若后续公司股票的收盘价格继续不低于当期转股价格的 130%（含130%，即17.49元/股），预计将可能触发"花园转债"的有条件赎回条 款。 根据《浙江花园生物医药股份有限公司向不特定对象发行可转换公司债券募 集说明书》（以下简称"《募集说明书》"）的有条件赎回条款，在本次发行的 可转换公司债券（以下简称"可转债"）转股期内，公司股票任何连续三十个交 易日中至少十五个交易日的收盘价格不低于当期转股价格的130%（含130%），公 司有权按照债券面值加当期应计利息的价格赎回全部或部分未转股的可转债。 若触发有条件赎回条款，公司将按 ...

Group 1 - Garden Biologics' stock increased by 5.42%, reaching 19.05 CNY per share, with a trading volume of 245 million CNY and a turnover rate of 2.47%, resulting in a total market capitalization of 10.353 billion CNY [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Among the top circulating shareholders of Garden Biologics, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 48,400 shares in the third quarter, now holding 3.4785 million shares, which is 0.65% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY. Year-to-date returns are 6.21%, ranking 1574 out of 5564 in its category; the one-year return is 39%, ranking 1777 out of 4288; and since inception, the return is 21.47% [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 93 days, managing total assets of 137.02 billion CNY. The best fund return during this period is 279.97%, while the worst is -15.93% [2]

Group 1 - The core point of the article is that Huayuan Bio (300401) reported a total of 23,584 shareholders as of January 30, 2026 [1]